<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598751</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-085-8</org_study_id>
    <nct_id>NCT03598751</nct_id>
  </id_info>
  <brief_title>Clinical Study of Efficacy and Safety of BCD-085 (Monoclonal Anti-IL-17 Antibody) in Psoriatic Arthritis</brief_title>
  <acronym>PATERA</acronym>
  <official_title>An International Multicenter Randomized Double-blind Placebo-controlled Clinical Study of the Efficacy and Safety of Subcutaneous BCD-085 in Patients With Psoriatic Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study BCD-085-8/PATERA is a multicentre double-blind placebo-controlled Phase 3 study in&#xD;
      patients with psoriatic arthritis (PsA). The objective of the study is to evaluate the&#xD;
      efficacy and safety of BCD-085 comparing to placebo in patients with PsA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 25, 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Actual">June 26, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR 20</measure>
    <time_frame>week 24</time_frame>
    <description>The percentage of patients achieved 20% improvement according to American College of Rheumatology response criteria.&#xD;
The ACR Criteria is a dichotomous variable with a positive (=responder) or negative (=non-responder) outcome. The ACR Criteria measures improvement in tender / swollen joint counts and improvement in at least three of the following parameters: 1) patient assessment 2) physician assessment 3) pain scale 4) disability/functional questionnaire 5) acute phase reactant (ESR or CRP). ACR 20 / 50 / 70 has a positive outcome if 20% / 50% / 70% improvement in tender and swollen joint counts was achieved as well as a 20% / 50% / 70% improvement in at least three of the other five criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR 20</measure>
    <time_frame>Week 1, 2, 4, 8, 12, 16, 20, 24, 30, 38, 46, 54</time_frame>
    <description>The percentage of patients achieved 20% improvement according to American College of Rheumatology response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 50</measure>
    <time_frame>Week 1, 2, 4, 8, 12, 16, 20, 24, 30, 38, 46, 54</time_frame>
    <description>The percentage of patients achieved 50% improvement according to American College of Rheumatology response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR 70</measure>
    <time_frame>Week 1, 2, 4, 8, 12, 16, 20, 24, 30, 38, 46, 54</time_frame>
    <description>The percentage of patients achieved 70% improvement according to American College of Rheumatology response criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieved PsARC (Psoriatic Arthritis Response Criteria)</measure>
    <time_frame>Week 1, 2, 4, 8, 12, 16, 20, 24, 30, 38, 46, 54</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in radiological signs of arthritis (mTSS)</measure>
    <time_frame>Week 24 and 54</time_frame>
    <description>mTSS - modified Total Sharp Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with anti-drug antibodies</measure>
    <time_frame>Week 2, Week 12, Week 24, Week 38, Week 54</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Psoriatic Arthritis</condition>
  <arm_group>
    <arm_group_label>BCD-085</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded period:&#xD;
BCD-085 120 mg at weeks 0, 1, 2, 4, 6, 8, 10, 14, 18, 22&#xD;
Open-label period:&#xD;
BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded period:&#xD;
Placebo at weeks 0, 1, 2, 4, 6, 8, 10, 14&#xD;
patients who don't achieve ACR 20 at week 16 will receive BCD-085 at weeks 18 and 22&#xD;
patients who achieve ACR 20 at week 16 will continue placebo at weeks 18 and 22&#xD;
Open-label period:&#xD;
BCD-085 120 mg at weeks 26, 30, 34, 38, 42, 46, 50, 54</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCD-085</intervention_name>
    <description>120 mg / 2 mL subcutaneously</description>
    <arm_group_label>BCD-085</arm_group_label>
    <other_name>Anti-interleukin-17 Monoclonal Antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 mL</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent (IC)&#xD;
&#xD;
          -  History of psoriatic arthritis (According to CASPAR, 2006) for 6 months&#xD;
&#xD;
          -  3/68 TJC and 3/66 SJC&#xD;
&#xD;
          -  RF / ACCP negative&#xD;
&#xD;
          -  At least 1 psoriatic plaque â‰¥ 2 cm and/or psoriatic nails and/or history of confirmed&#xD;
             plaque psoriasis&#xD;
&#xD;
          -  History of inadequate response to NSAID&#xD;
&#xD;
          -  Stable dose of NSAID for 2 weeks&#xD;
&#xD;
          -  If on steroids: inadequate response to steroids (at least 3 months of treatment) and&#xD;
             stable dose of steroids (10 mg or less) for at least 2 weeks.&#xD;
&#xD;
          -  If on MTX: inadequate response to MTX (stable dose 15 - 25 mg / week for at least 2&#xD;
             months)&#xD;
&#xD;
          -  In case of history of etanercept therapy: at least 4 weeks after last administration&#xD;
&#xD;
          -  In case of history of infliximab therapy: at least 8 weeks after last administration&#xD;
&#xD;
          -  In case of history of adalimumab / golimumab / certolizumab pegol therapy: at least 10&#xD;
             weeks after last administration&#xD;
&#xD;
          -  In case of history of other mabs / fragments / small molecules : at least 5 half life&#xD;
             after last administration&#xD;
&#xD;
          -  Negative pregnancy test for women with childbearing potential&#xD;
&#xD;
          -  Ability to follow procedures of the study&#xD;
&#xD;
          -  Patient and his/her sexual partner with childbearing potential are ready to use&#xD;
             reliable contraception, starting at the date of IC sign, within the study period and 4&#xD;
             weeks after the last dose of investigational drug administration. (Not applied to&#xD;
             participants/sexual partners who surgically sterilized, and women at menopause for&#xD;
             more than 2 years). Reliable contraception considered as 1 barrier method and one of&#xD;
             the following: spermicides, oral contraception or intrauterine devices)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Therapy with anti-IL17 / IL17R or anti-IL12/23 or history of therapy with 2 or more&#xD;
             monoclonal antibodies or therapy with topical / oral retinoids or phototherapy or&#xD;
             other topical medication for psoriasis history or parenteral steroids administration&#xD;
             or any intraarticular injections within 4 weeks prior IC sign or any DMARD therapy&#xD;
             (excl. methotrexate) on the dated of IC&#xD;
&#xD;
          -  Vaccination with live vaccines within 8 weeks prior to IC sign&#xD;
&#xD;
          -  Diagnosis of any other chronic infection which may increase the risk of infectious&#xD;
             adverse events.&#xD;
&#xD;
          -  HIV, HCV, HBV, Syphilis.&#xD;
&#xD;
          -  Clinically significant deviations in blood chemistry and blood count&#xD;
&#xD;
          -  History of Herpes Zoster&#xD;
&#xD;
          -  History of depression, suicidal ideation/behavior.&#xD;
&#xD;
          -  Known history of alcohol or drug abuse&#xD;
&#xD;
          -  Diagnosis or history of tuberculosis&#xD;
&#xD;
          -  Any acute infection or chronic infection flare within 30 days prior to informed&#xD;
             consent sign, which may increase (according to the PI opinion) the risk of infectious&#xD;
             adverse events.&#xD;
&#xD;
          -  Any other documented conditions which increase the risk of AEs development or may&#xD;
             interfere with symptoms the disease (masking, increasing or changing) or induce&#xD;
             clinical symptoms or laboratory abnormalities similar to PsA:&#xD;
&#xD;
               1. Uncontrolled diabetes mellitus;&#xD;
&#xD;
               2. Severe, uncontrolled hypertension;&#xD;
&#xD;
               3. Presence or history of inflammatory joint disease other than PsA (or any other&#xD;
                  systemic autoimmune disease (including lupus, Crohn's disease, ulcerative&#xD;
                  colitis, scleroderma, inflammatory myopathy, mixed connective tissue disease,&#xD;
                  autoimmune overlap syndrome, fibromyalgia etc.);&#xD;
&#xD;
               4. History of malignancy, excluding cured basal cell carcinoma / cervical cancer in&#xD;
                  situ (complete remission for 5 years); cured basal cell skin carcinoma (5 years&#xD;
                  complete remission), cured ductal breast cancer (5 years complete remission);&#xD;
&#xD;
               5. Decompensated liver or kidney diseases;&#xD;
&#xD;
               6. Unstable angina pectoris;&#xD;
&#xD;
               7. Chronic heart failure, class III-IV according to NYHA;&#xD;
&#xD;
               8. Myocardial infarction, within 1 year prior to IC sign;&#xD;
&#xD;
               9. History of organ transplantation;&#xD;
&#xD;
              10. History of Quincke edema;&#xD;
&#xD;
              11. History of any significant respiratory diseases, including COPD, asthma or&#xD;
                  bronchiectasis;&#xD;
&#xD;
              12. Decompensated respiratory failure;&#xD;
&#xD;
              13. History of multiple sclerosis,&#xD;
&#xD;
              14. Devic's disease, or Guillain-Barre syndrome;&#xD;
&#xD;
              15. Any neurological disease with motor or sensory functions impairment)&#xD;
&#xD;
          -  Pregnancy, current or planned in less than 8 weeks after study completion or&#xD;
             breastfeeding.&#xD;
&#xD;
          -  Simultaneous participation in other clinical trials or participation in other clinical&#xD;
             trials with 3 month prior to IC signing date or history of participation it current&#xD;
             clinical study (excluding patients dropped out at screening).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Ivanov, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Biocad</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1st City Clinical Hospital</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical hospital</name>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North-Western State Medical University n.a. I.I.Mechnikov</name>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 16, 2018</study_first_submitted>
  <study_first_submitted_qc>July 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

